|Bid||3.2200 x 3100|
|Ask||3.2800 x 2200|
|Day's range||2.9501 - 3.7400|
|52-week range||2.8700 - 8.5800|
|Beta (5Y monthly)||0.95|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Bluebird (BLUE) delivered earnings and revenue surprises of -26.67% and 99.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The past several years have been brutal for biotech company Bluebird bio (NASDAQ: BLUE). Shares of the gene-editing specialist are down by 85% since early 2020 as it has had to deal with clinical and regulatory setbacks, not to mention the marketwide headwinds that have impacted all equities.